Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse and / or Refractory Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00594126
What this trial is testing

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Geron Corporation 20
Testing effectiveness (Phase 2)Study completedNCT03267888
What this trial is testing

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
ISS Stage I Plasma Cell MyelomaISS Stage II Plasma Cell MyelomaISS Stage III Plasma Cell Myeloma+2 more
Emory University 25
Early research (Phase 1)Study completedNCT00741377
What this trial is testing

Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Who this might be right for
Multiple Myeloma Bone Disease
Novartis Pharmaceuticals 28
Early research (Phase 1)Study completedNCT02546167
What this trial is testing

CART-BCMA Cells for Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Pennsylvania 25
Not applicableStudy completedNCT00376922
What this trial is testing

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+7 more
Wake Forest University Health Sciences 65
Early research (Phase 1)Looking for participantsNCT04771572
What this trial is testing

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Who this might be right for
Non Hodgkin LymphomaRichter TransformationMultiple Myeloma+10 more
Newave Pharmaceutical Inc 100
Early research (Phase 1)Not Yet RecruitingNCT06500507
What this trial is testing

QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd. 90
Early research (Phase 1)Study completedNCT02101944
What this trial is testing

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
AnemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)UnknownNCT00334932
What this trial is testing

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Herbert Irving Comprehensive Cancer Center 32
Testing effectiveness (Phase 2)Ended earlyNCT03837509
What this trial is testing

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Incyte Corporation 15
Testing effectiveness (Phase 2)Looking for participantsNCT07479979
What this trial is testing

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapse Multiple MyelomaRefractory Multiple Myeloma
Natalie Callander 62
Early research (Phase 1)Study completedNCT01330173
What this trial is testing

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Who this might be right for
DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell Myeloma+1 more
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Study completedNCT00047203
What this trial is testing

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT00511082
What this trial is testing

Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Who this might be right for
Non-Hodgkin's Lymphoma(NHL)Multiple Myeloma
Otsuka Beijing Research Institute 7
Early research (Phase 1)Ended earlyNCT04171843
What this trial is testing

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Precision BioSciences, Inc. 48
Very early researchWithdrawnNCT02971410
What this trial is testing

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Wake Forest University Health Sciences
Early research (Phase 1)WithdrawnNCT05950113
What this trial is testing

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06297226
What this trial is testing

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 230
Testing effectiveness (Phase 2)Looking for participantsNCT06103838
What this trial is testing

18F-Fluciclovine PET/CT in Multiple Myeloma

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 60
Early research (Phase 1)Active Not RecruitingNCT06215118
What this trial is testing

Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Who this might be right for
Multiple Myeloma
Pfizer 100
Next Page